Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Archer-Daniels-Midland Co (ADM) vs BIO-TECHNE Corp (TECH) Price & Performance

Archer-Daniels-Midland Co
BIO-TECHNE Corp

Price performance

Price movement over the last 24 hours

Key statistics

Archer-Daniels-Midland Co vs BIO-TECHNE Corp — how do they compare? Archer-Daniels-Midland Co trades at $79.97 (market cap $37.69B), while BIO-TECHNE Corp trades at $70.6 (market cap $11.00B). The key difference: Archer-Daniels-Midland Co is far larger — about 3.4× BIO-TECHNE Corp's market cap, and Archer-Daniels-Midland Co pays the higher dividend (2.66%). Which is the better fit depends on your goals.

ADMTECH
Market Cap
$37.69B$11.00B
Sector
Consumer StaplesHealth
52-Week High
$84.11$71.38
52-Week Low
$53.54$43.31
Enterprise Value
$47.72B$11.08B
Dividend Yield
2.66%0.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Archer-Daniels-Midland Co

ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.

Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $70.61, down 0.3% on the day, near its $73.00 takeover offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with strong moving averages, though RSI levels indicate overbought conditions. Fundamentals reveal a high P/E of 101.29 and declining net margins, but revenue remains stable near $1.22 billion. Cash flow improved in 2025 with $10.40M net inflow, and the balance sheet holds $152.86M cash against $319M long-term debt.

Outlook is dominated by the pending acquisition, offering a clear exit at $73.00, a 3.4% premium to current price. Risks include shareholder litigation questioning deal fairness and margin pressures. Analysts are unanimously positive with no sell ratings, seeing limited downside given the buyout bid. The stock presents a low-risk opportunity if the deal closes, but investors face uncertainty from legal challenges and earnings volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Archer-Daniels-Midland Co

Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.

Read more on ADM

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH